MAPT and Alzheimer disease: The major biomarkers of AD that are typically considered for clinical trials and observational studies are cerebrospinal fluid (CSF) Aβ1-42, CSF total-tau (t-tau), fluoro-deoxy-glucose positron emission tomography (FDG–PET), Pittsburgh compound B-PET (PIB–PET), and sMRI.